10X Genomics Inc - Asset Resilience Ratio
10X Genomics Inc (TXG) has an Asset Resilience Ratio of 4.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check TXG strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how 10X Genomics Inc's Asset Resilience Ratio has changed over time. See TXG equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down 10X Genomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TXG company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $49.58 Million | 4.83% |
| Total Liquid Assets | $49.58 Million | 4.83% |
Asset Resilience Insights
- Limited Liquidity: 10X Genomics Inc maintains only 4.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
10X Genomics Inc Industry Peers by Asset Resilience Ratio
Compare 10X Genomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS |
Health Information Services | 0.39% |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY |
Health Information Services | 2.13% |
|
DocCheck AG
XETRA:AJ91 |
Health Information Services | 7.30% |
|
Pro Medicus Ltd
AU:PME |
Health Information Services | 54.64% |
|
Echoiq Ltd
AU:EIQ |
Health Information Services | 11.12% |
|
ARTRYA Ltd
AU:AYA |
Health Information Services | 32.70% |
|
Cogstate Ltd
AU:CGS |
Health Information Services | 54.90% |
|
Oneview Healthcare Plc
AU:ONE |
Health Information Services | 29.71% |
Annual Asset Resilience Ratio for 10X Genomics Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for 10X Genomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.37% | $49.34 Million | $918.64 Million | +2.32pp |
| 2023-12-31 | 3.05% | $29.41 Million | $965.14 Million | -17.38pp |
| 2022-12-31 | 20.43% | $210.24 Million | $1.03 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $1.02 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $124.31 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $75.61 Million | -- |
About 10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more